KRT19 and breast cancer: In a study with a total of 444 BC patients (stages I–III) who received adjuvant chemotherapy, and had a follow-up of 10 months with adjuvant chemotherapy regimens, the patients presenting CK-19 (cytokeratin-19) mRNA-positive CTCs experienced reduced disease-free survival (DFS) and overall survival (OS) after treatment [50].